Review

Not peer-reviewed version

Advancements in Nuclear Medicine Through Artificial Intelligence: A Comprehensive Review

Emir Oncu *

Posted Date: 3 January 2025

doi: 10.20944/preprints202501.0158.v1

Keywords: artificial intelligence; nuclear medicine; PET; SPECT; molecular imaging; deep learning

Review

Advancements in Nuclear Medicine Through Artificial Intelligence: A Comprehensive Review

Emir Oncu

Fatih Sultan Mehmet Vakıf University, Turkey; biomedical.emr@gmail.com

Abstract: Artificial intelligence (AI) has emerged as a transformative tool in nuclear imaging, offering innovative solutions to enhance diagnostic accuracy, image quality, and clinical workflows. This article explores the integration of AI methodologies, including deep learning and traditional machine learning models, into nuclear imaging modalities such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). By leveraging advanced algorithms, AI addresses longstanding challenges in noise reduction, resolution enhancement, and tumor classification. Key findings demonstrate the application of AI in improving cancer detection, delineating tumor volumes, and predicting patient outcomes with unparalleled precision. The study highlights how convolutional neural networks (CNNs), generative adversarial networks (GANs), and vision transformers (ViTs) are revolutionizing medical imaging through superior image reconstruction and analysis capabilities. Limitations, such as the dependency on large, annotated datasets and ethical concerns, are discussed alongside future directions, including the integration of multi-modal imaging data and real-time AI applications. In conclusion, AI represents a paradigm shift in nuclear imaging, advancing personalized medicine and improving patient outcomes. However, further research is required to address challenges and unlock its full potential in clinical practice.

Keywords: artificial intelligence; nuclear medicine; PET; SPECT; molecular imaging; deep learning

1. Introduction

Nuclear medicine is a critical branch of medical imaging that utilizes radiopharmaceuticals to visualize, diagnose, and treat various diseases. Nuclear medicine offers distinct insights into physiological and biochemical alterations by concentrating on the body's functional processes, in contrast to traditional imaging modalities like MRIs and X-rays. By allowing the detection of anomalies at the molecular level, techniques like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have transformed diagnostics into cardiology, neurology, and oncology. Gamma rays are captured using a 2-D planar gamma camera in traditional nuclear medicine. Adding single-photon emission computed tomography, or SPECT, improves accuracy and sensitivity [1]. Obtaining both SPECT and CT offers anatomic reference and enhances accuracy even further. PET (positron emission tomography) is now frequently obtained in conjunction with CT (PET/CT), and PET/MR has lately become more accessible [2]. PET imaging has steadily gained popularity and is now used to treat a wide range of cancer and non-cancer conditions. FDG-PET/CT can have significant limitations even if it has been shown to produce satisfactory diagnostic accuracy in a variety of inflammatory and infectious disorders and in the right clinical environment. Specifically, FDG PET/CT's frequently subpar specificity can lead to needless biopsies or even treatments with known side effects that aren't necessarily warranted by the suspected underlying illness, and how to deal with these [3].

 doi:10.20944/preprints202501.0158.v1

1.1. Artificial Intelligence and Its Role in Healthcare

AI is becoming a crucial component in nuclear medicine. picture analysis, picture pre- and post-processing, therapy adverse reaction prediction, and staging category optimization are just a few of the methods that have already made use of it [4]. AI offers promising solutions to overcome the specific limitations of FDG-PET/CT. Advanced AI algorithms can enhance image analysis by distinguishing between benign and malignant lesions or inflammatory versus infectious processes with greater accuracy, reducing false positives. Machine learning models trained on large, annotated datasets can identify subtle patterns that may be missed by traditional analysis, improving diagnostic precision. Although AI has been studied since the 1950s, its use in healthcare has only recently advanced from theory to practice. In its most basic form, AI is the ability of a computer program to reason, think, learn, react, and adapt to solve problems in a way that is like that of a human. Radiomics is the process of extracting quantitative information from medical images that have clinical significance. It can provide useful diagnostic and prognostic information. There are various AI approaches. A form of artificial intelligence known as machine learning (ML) allows a computer (referred to as "the machine") to learn from data it has been exposed to without the need for prior programming. Both supervised and unsupervised modes of operation are possible [5]. Annotated cases, such as actual patient photos, reports, and records with known outcomes, can be used to "train" an ML software in imaging practice so that it can anticipate the diagnosis of future cases (supervised learning) [6].

Medical diagnostics has undergone a revolution because of CNNs, which automate difficult image analysis tasks with high efficiency and accuracy [7]. CNNs have proven very useful in the analysis of medical images, where subtle variations are essential for diagnosis, because of their ability to learn hierarchical characteristics from images. Numerous medical imaging specialties, such as radiology, pathology, dermatology, and ophthalmology, have made extensive use of CNNs, showcasing their adaptability and potential to enhance patient outcomes by accurately classifying disorders and detecting them early. Convolutional Neural Networks (CNNs) are essential to MRI analysis because they can extract hierarchical features from complex images. CNNs are widely used to classify different brain illnesses, which enables the identification of specific tumor types such gliomas, meningiomas, and pituitary tumors. Enhanced CNN designs, such VGGNet and ResNet, incorporate deeper layers and residual connections to improve accuracy by gathering more intricate information from MRI scans [8]. InceptionV3, another well-known model, improves the classification process and allows the network to gather both small and large features in MRI images by using parallel convolutional layers with varying filter widths [9]. This flexibility has proven particularly useful in spotting subtle patterns and abnormalities that traditional imaging techniques would overlook. With its creative answers to enduring problems in diagnosis, treatment planning, and patient management, AI has become a disruptive force in contemporary healthcare. AI systems, which are based on sophisticated algorithms, can process enormous volumes of data with previously unheard-of speed and precision, empowering medical professionals to make better judgments. AI is changing the way diseases are identified and treated, from customized medicine to predictive analytics. AI has demonstrated great potential in improving diagnosis accuracy in the field of medical imaging, particularly when applied to methods like deep learning and neural networks. AI can improve diagnosis accuracy and lower false positives by evaluating complicated information, like those produced by FDG-PET/CT scans, and spotting patterns and abnormalities that the human eye might miss. Pharmaceutical companies have accelerated their drug discovery process with the use of AI in healthcare. In contrast, it automates the process of identifying targets. Additionally, AI in healthcare 2021 facilitates drug repurpose by identifying off-target chemicals [10]. There are several solutions that the top biopharmaceutical companies have found. Pfizer is looking for immuno-oncology medicines with the aid of IBM Watson, a machine learning-based system. While Roche subsidiary Genentech is depending on an artificial intelligence system from GNS Healthcare in Cambridge, Massachusetts, to help in its hunt for cancer treatments, Sanofi has decided to use Exscientia's AI platform to look for drugs for metabolic diseases [11]. Nearly all the big biopharmaceutical companies have similar internal programs or partnerships. This article explores the transformative impact of AI on nuclear medicine, focusing on how AI addresses key challenges and limitations in imaging techniques like FDG-PET/CT. It delves into the integration of AI-driven algorithms to enhance diagnostic accuracy, optimize treatment planning, and improve the efficiency of clinical workflows. By combining traditional radiopharmaceutical imaging methods with state-of-the-art machine learning approaches, the article demonstrates AI's potential to revolutionize the field, offering innovative solutions for image analysis, tumor classification, and therapy optimization. Additionally, the review examines the broader implications of AI in healthcare, from drug discovery to personalized medicine, highlighting its multidisciplinary influence and prospects.

2. Methods

Nuclear medicine enables the visualization and quantification of organ function through the analysis of radiopharmaceutical uptake. Radiopharmaceuticals emit gamma photons either directly through gamma decay or indirectly via positron emissions, which trigger annihilation interactions detected by imaging systems [12]. These processes yield both qualitative and quantitative data essential for assessing organ functionality. Key parameters influencing image quality include energy separation power, counting sensitivity, and spatial resolution [13]. Energy separation power, also known as spatial separation power, defines the imaging system’s capacity to distinguish between two distinct characteristics, such as energy levels or spatial features. Superior spatial resolution ensures that distinct anatomical structures are differentiated, provided the distance between them exceeds the system’s spatial discrimination power. For instance, in SPECT imaging, low-energy, high-resolution collimators improve spatial resolution at the expense of sensitivity [14]. Such trade-offs necessitate compensatory measures, including increasing administered activity or imaging duration, though these approaches may lead to increased patient dosage or artifacts due to motion [15].

2.1. Image Enhancement Techniques in PET Imaging

Enhancing PET (Positron Emission Tomography) image quality is critical for accurate diagnosis and interpretation [16]. Several advanced techniques are employed:

- **Noise Reduction**: Sophisticated algorithms minimize inherent noise, improving the clarity and reliability of images [17]. Methods such as Gaussian smoothing and non-local means filtering are commonly utilized.
- **Resolution Enhancement**: Point spread function (PSF) modeling sharpens image details, facilitating the visualization of small or low-contrast structures [18].
- **Attenuation Correction**: Techniques like CT-based attenuation correction or segmentation-based methods ensure accurate tracer uptake quantification, essential for reliable clinical assessments [19].
- **Motion Correction**: Patient movement during scanning is a significant source of artifacts. Advanced motion correction algorithms mitigate these effects, preserving diagnostic accuracy [20].
- **Image Fusion**: Combining PET with complementary modalities such as CT or MRI integrates anatomical and functional data, providing enhanced diagnostic capabilities [21].

2.2. Image Enhancement Techniques in SPECT Imaging

SPECT (Single Photon Emission Computed Tomography) imaging faces challenges like PET but employs specific methodologies to optimize image quality:

- **Noise Reduction:** Advanced filtering techniques, such as iterative reconstruction algorithms and adaptive smoothing, balance noise reduction with the preservation of critical details [22].
- **Resolution Recovery:** Algorithms designed to correct collimators, blurring optimizes spatial resolution, enabling better visualization of anatomical structures and pathological features [23].

Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 3 January 2025 doi:10.20944/preprints202501.0158.v1

- **Attenuation Correction:** Techniques such as CT-based methods or iterative attenuation correction approaches account for tissue absorption, enhancing quantification accuracy [24].
- **Motion Correction:** Addressing patient movement during scans reduces motion artifacts, ensuring clarity in image interpretation [17].
- **Quantitative Analysis:** Methods like standardized uptake value (SUV) calculations provide precise quantification of radiotracer distribution, essential for assessing metabolic activity [22].

2.3. Role of AI in Image Enhancement

AI is revolutionizing image enhancement in both PET and SPECT imaging by leveraging advanced algorithms to address traditional limitations. AI-driven noise reduction techniques, powered by CNNs, ensure that fine details are preserved while artifacts are minimized. Additionally, AI-based attenuation and motion correction systems provide automated, real-time solutions that adapt to patient-specific imaging conditions. State-of-the-art AI techniques employed in nuclear medicine imaging often utilize CNNs with encoder-decoder architectures. The encoder compresses input data into latent representations through down-sampling, while the decoder reconstructs high-quality images via up-sampling. Common components include:

- **Convolution Layers (Conv):** Extract spatial features from input data [25].
- **Rectified Linear Units (ReLU):** Introduce non-linearity for feature extraction [26].
- **Max Pooling:** Reduce spatial dimensions while retaining key features.
- **Up-sampling Layers (UpConv):** Restore image dimensions to match the original input [27].

AI models for nuclear imaging are trained using both supervised and unsupervised frameworks:

- **Supervised Learning**: Paired datasets—consisting of high- and low-quality images—are used to train models to enhance image quality [28]. However, acquiring such datasets is often challenging due to the need for dual scans or access to raw imaging data.
- **Unsupervised Learning**: These frameworks rely solely on noisy or tainted input data, eliminating the requirement for paired datasets [29]. Techniques such as generative adversarial networks (GANs) and self-supervised learning are gaining popularity in this domain.

Imaging systems consist of critical components such as detectors, collimators, and reconstruction algorithms. Detector efficiency and collimator design significantly influence attributes like spatial and energy resolution. For example, while low-energy, high-resolution collimators enhance spatial resolution in SPECT systems, they may necessitate increased activity administration to counterbalance reduced sensitivity. Prolonged imaging durations are an alternative, though they risk patient discomfort and motion-induced artifacts.

3. AI Methodologies in Nuclear Imaging

AI methodologies have demonstrated immense potential in enhancing nuclear imaging by addressing challenges in diagnostic accuracy, image quality, and clinical interpretation. These methodologies leverage advanced algorithms to process complex imaging datasets, offering novel solutions to long-standing limitations in techniques like PET and SPECT. Deep learning models, particularly CNNs are at the forefront of AI advancements in nuclear imaging. CNNs excel at extracting hierarchical features from medical images, enabling accurate classification, segmentation, and enhancement of PET and SPECT images. Enhanced CNN architectures, such as ResNet, VGGNet, and InceptionV3, incorporate deeper layers, residual connections, and parallel convolutions to improve performance and capture intricate patterns within imaging data. For example, ResNet's residual connections mitigate the vanishing gradient problem, allowing the network to learn more complex features, while InceptionV3's multi-scale feature extraction aids in detecting both subtle and prominent abnormalities. Generative Adversarial Networks (GANs) have further revolutionized nuclear imaging by enabling high-quality image reconstruction and noise reduction. GANs consist of two networks—a generator and a discriminator—that compete to produce realistic images from noisy or incomplete inputs. This capability is particularly valuable in PET imaging, where GANs

 doi:10.20944/preprints202501.0158.v1

enhance resolution and reduce artifacts caused by low photon counts. Transformers, originally designed for natural language processing, have recently been adapted for medical imaging tasks. Vision Transformers (ViTs) utilize self-attention mechanisms to capture global dependencies within imaging data, offering superior performance in tasks like tumor detection and segmentation [30]. These models are especially effective in analyzing complex, high-dimensional datasets, such as those generated in nuclear imaging. Traditional ML models, though less complex than deep learning frameworks, have proven effective in certain nuclear imaging applications. Algorithms such as support vector machines (SVMs), random forests, and k-nearest neighbors (k-NN) are widely used for tasks like feature selection and classification. For instance, SVMs have been employed to differentiate between benign and malignant lesions in PET/CT scans by leveraging handcrafted radiomic features. While ML models are computationally efficient and require less data compared to deep learning, they often rely on manual feature extraction, which can limit their scalability and generalizability. However, these models remain valuable in scenarios where data availability is constrained or when computational resources are limited.

Performance Metrics of AI Models for PET vs. SPECT AI models demonstrate distinct performance characteristics when applied to PET and SPECT imaging, reflecting the unique challenges and opportunities of each modality:

- **PET Imaging:** Deep learning models, particularly CNNs and GANs, excel in PET imaging due to their ability to handle high-dimensional data and enhance image quality. Metrics such as sensitivity, specificity, and dice similarity coefficient (DSC) consistently show improvements with AI integration [31]. GANs have been instrumental in addressing low-count imaging challenges, reducing noise while preserving diagnostic accuracy.
- **SPECT Imaging:** AI applications in SPECT imaging often focus on noise reduction, resolution recovery, and attenuation correction. CNNs and traditional ML models are commonly employed, with performance metrics demonstrating significant enhancements in spatial resolution and quantification accuracy. However, the inherently lower photon counts, and resolution of SPECT compared to PET present challenges that AI models are actively addressing through innovative reconstruction techniques.

Table 1 summarizes a variety of research studies that leverage AI models to address different types of cancers using PET and SPECT imaging techniques. Lung cancer emerges as the most frequently studied cancer type, with AI models being employed to predict malignancy, delineate tumors, and enhance diagnostic accuracy. Other cancers, such as pancreatic, lymphoma, head and neck cancers, and soft tissue sarcoma, have also been investigated to explore the potential of AI in medical imaging applications.

Author and Year	Type of Cancer	Population of the Study	Purpose of the Study
Ailou, 2018 [32]	Lung	145 patients for training and 145 for validation	Differentiating granulomas
Scott, 2019 [33]	Lung	85 patients for training and 45 for testing	Prediction of malignancy in ground glass opacities
Wu, 2018 [34]	Lung	186 patients	Cancer Detection
Peng, 2019 [32]	Soft Tissue Sarcoma	48 patients with pathology-proven sarcoma	Prediction of distant metastasis

 doi:10.20944/preprints202501.0158.v1

Zhong, 2019 [35]	Lung	38 patients for training and 22 for testing	Gross Tumor Volume Segmentation
Dong, 2020 [36]	Lung, Lymphoma, Skin, Breast, Abdominal	25 patients for training and 55 for evaluation	Correction in Whole-body PET Imaging
Ellmann, 2019 [37]	Breast	28 rats	Prediction of Early Metastasis for Bones

AI applications extend beyond specific cancer types, enabling tasks such as predicting metabolic activity (SUVmax) in lymph nodes and improving attenuation correction in PET imaging without the need for additional structural scans. Such advancements underscore the transformative potential of AI in enhancing diagnostic workflows, reducing false positives, and enabling early detection and personalized treatment strategies in oncology.

- **Lung Cancer**: AI has been extensively used to predict survival and prognosis in lung cancer patients. Studies leveraging PET and CT images have demonstrated the superior performance of AI models over traditional radiomics approaches, particularly in differentiating benign from malignant lesions.
- **Head and Neck Cancer**: Deep learning models excel in tumor delineation and segmentation, accurately outlining tumor volumes compared to manual methods, thereby improving precision in treatment planning.
- **Lymphoma**: AI models classify lymphoma PET/CT images with high accuracy, distinguishing normal from abnormal metabolic patterns and automating response assessments based on standardized criteria.
- **Pancreatic Cancer**: PET/CT-based AI models enhance the detection and classification of pancreatic cancer, achieving high sensitivity in identifying cancerous regions and segmenting pancreatic structures.
- **Breast Cancer and Bone Metastasis**: AI techniques predict early metastatic disease in breast cancer patients using PET/CT and MRI images, demonstrating exceptional accuracy in identifying bone metastases.
- **Soft Tissue Sarcoma**: AI algorithms predict distant metastases with greater precision compared to conventional imaging analysis, showcasing their potential in rare cancer types.

4. Discussion

The integration of AI into nuclear imaging represents a significant leap forward in the fields of medical diagnostics and oncology. This study highlights the diverse applications of AI methodologies, from image enhancement to tumor classification and personalized treatment strategies, across PET and SPECT imaging modalities. The ability of AI models, particularly deep learning architectures, to process and analyze high-dimensional datasets has been a game-changer, overcoming many limitations associated with traditional imaging techniques.

One of the key findings of this study is the marked improvement in diagnostic accuracy facilitated by AI. For instance, CNNs and GANs have significantly enhanced the resolution and quality of PET and SPECT images, enabling early and precise tumor detection. By mitigating noise, correcting for motion artifacts, and optimizing attenuation correction, these models have improved the reliability of imaging results, particularly in complex cases such as low photon counts in PET imaging or suboptimal spatial resolution in SPECT imaging. Another critical observation is the versatility of AI in addressing a broad spectrum of cancers. From lung cancer to soft tissue sarcoma, AI has demonstrated its capacity to enhance diagnostic workflows, as shown by its application in tumor delineation, volume segmentation, and prognosis prediction. Particularly notable is AI's performance in distinguishing benign from malignant lesions, a challenge that has historically plagued traditional methods like FDG-PET/CT. By integrating patient history and imaging features, AI algorithms have reduced false positives, thereby minimizing unnecessary biopsies and treatments. Despite these advances, challenges remain in the clinical translation of AI technologies. A primary concern is the generalizability of AI models across different datasets and clinical environments. While supervised learning models deliver exceptional accuracy, their reliance on large, annotated datasets poses a significant limitation. Unsupervised and self-supervised learning frameworks are emerging as promising alternatives but require further validation. Additionally, ethical considerations, such as data privacy and algorithmic bias, must be addressed to ensure equitable and transparent AI implementation in healthcare. The comparison between PET and SPECT imaging further underscores the unique challenges and opportunities presented by each modality. AI models have been particularly effective in PET imaging, with metrics like sensitivity, specificity, and dice similarity coefficient showing significant improvements. In SPECT imaging, where photon counts and resolution are inherently lower, AI-driven reconstruction techniques are actively addressing these limitations, albeit with room for further development.

4.1. Limitations and Future Works

The future of artificial intelligence (AI) in nuclear imaging is promising but requires addressing several key challenges and exploring untapped opportunities. Future research should focus on developing more robust and generalizable AI models capable of performing across diverse datasets and clinical environments. Collaborative efforts across institutions and regions are essential to create large-scale, standardized datasets that can enhance model training and validation. One critical area for future exploration is the integration of multi-modal imaging data, such as combining PET, SPECT, CT, and MRI, to create comprehensive diagnostic tools. AI algorithms that can synthesize information from various modalities have the potential to improve diagnostic accuracy and provide deeper insights into disease processes. Additionally, the application of transfer learning and domain adaptation techniques can help adapt existing AI models to new imaging modalities or underrepresented populations, reducing the need for extensive retraining. The incorporation of real-time AI applications during imaging procedures is another exciting avenue for development. AI systems that provide immediate feedback and adjust imaging parameters dynamically could significantly improve image quality and reduce scanning times. Moreover, advancements in explainable AI are crucial to address the black-box nature of many AI models, fostering trust and understanding among clinicians and patients [38]. Despite its potential, AI in nuclear imaging faces notable limitations. The reliance on large, high-quality datasets is a significant barrier, particularly in regions with limited access to advanced imaging technologies. Additionally, ethical concerns, such as data privacy, algorithmic bias, and the risk of over-reliance on AI at the expense of clinical judgment, must be carefully managed. Regulatory hurdles and the lack of clear guidelines for the deployment of AI in healthcare further impede its widespread adoption.

5. Conclusion

In this paper, we emphasized that AI has undeniably transformed the landscape of nuclear imaging, offering unprecedented advancements in diagnostic accuracy, image quality, and clinical utility. By leveraging advanced AI methodologies, particularly deep learning models, nuclear imaging techniques such as PET and SPECT have been significantly enhanced, enabling earlier and more accurate detection of various cancers and other diseases. The applications of AI extend beyond mere image processing; they encompass tumor classification, treatment planning, and prognostic assessments, paving the way for personalized medicine. Despite these advancements, challenges persist in ensuring the generalizability and ethical deployment of AI technologies in clinical practice.

The reliance on large, annotated datasets and the need for standardized validation frameworks highlight areas that require further development. Additionally, interdisciplinary efforts are crucial to address the technical, ethical, and regulatory challenges that accompany the integration of AI into healthcare systems.

In summary, AI represents a paradigm shift in nuclear imaging, transforming it into a more precise, efficient, and patient-centered discipline. As research and development in AI continue to advance, its integration into routine clinical workflows holds the promise of improved healthcare outcomes and a new era of innovation in medical imaging.

References

1. A. Saleh, "Comparative shielding features for X/Gamma-rays, fast and thermal neutrons of some gadolinium silicoborate glasses," *Progress in Nuclear Energy*, vol. 154, p. 104482, Dec. 2022. https://doi.org/10.1016/J.PNUCENE.2022.104482.
2. P. Ritt, "Recent Developments in SPECT/CT," *Semin Nucl Med*, vol. 52, no. 3, pp. 276–285, May 2022. https://doi.org/10.1053/J.SEMNUCLMED.2022.01.004.
3. J. P. Pijl, P. H. Nienhuis, T. C. Kwee, A. W. J. M. Glaudemans, R. H. J. A. Slart, and L. C. Gormsen, "Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation," *Semin Nucl Med*, vol. 51, no. 6, pp. 633–645, Nov. 2021. https://doi.org/10.1053/J.SEMNUCLMED.2021.06.008.
4. F. Nensa, A. Demircioglu, and C. Rischpler, "Artificial intelligence in nuclear medicine," *Journal of Nuclear Medicine*, vol. 60, no. 9, pp. 29S-37S, Sep. 2019. https://doi.org/10.2967/jnumed.118.220590.
5. Y. Bengio, Y. Lecun, and G. Hinton, "Deep learning for AI," *Commun ACM*, vol. 64, no. 7, pp. 58–65, Jun. 2021. https://doi.org/10.1145/3448250.
6. W. Parker *et al.*, "Canadian Association of Radiologists White Paper on De-identification of Medical Imaging: Part 2, Practical Considerations," Feb. 01, 2021, *SAGE Publications Inc. https://doi.org/*10.1177/0846537120967345.
7. D. Bhatt *et al.*, "Cnn variants for computer vision: History, architecture, application, challenges and future scope," Oct. 01, 2021, *MDPI*. https://doi.org/10.3390/electronics10202470.
8. M. F. Haque, H. Y. Lim, and D. S. Kang, "Object detection based on VGG with ResNet network," in *ICEIC 2019 - International Conference on Electronics, Information, and Communication*, Institute of Electrical and Electronics Engineers Inc., May 2019. https://doi.org/10.23919/ELINFOCOM.2019.8706476.
9. S. Sridhar *et al.*, "A Torn ACL Mapping in Knee MRI Images Using Deep Convolution Neural Network with Inception-v3," *J Healthc Eng*, vol. 2022, 2022. https://doi.org/10.1155/2022/7872500.
10. Ó. Díaz, J. A. R. Dalton, and J. Giraldo, "Artificial Intelligence: A Novel Approach for Drug Discovery," Aug. 01, 2019, *Elsevier Ltd*. https://doi.org/10.1016/j.tips.2019.06.005.
11. P. Agrawal, "Artificial Intelligence in Drug Discovery and Development," *J Pharmacovigil*, vol. 06, no. 02, 2018. https://doi.org/10.4172/2329-6887.1000e173.
12. K. Vermeulen, M. Vandamme, G. Bormans, and F. Cleeren, "Design and Challenges of Radiopharmaceuticals," *Semin Nucl Med*, vol. 49, no. 5, pp. 339–356, Sep. 2019. https://doi.org/10.1053/J.SEMNUCLMED.2019.07.001.
13. S. Vallabhajosula, "Positron Emission Tomography Radiopharmaceuticals for Imaging Brain Beta-Amyloid," *Semin Nucl Med*, vol. 41, no. 4, pp. 283–299, Jul. 2011. https://doi.org/10.1053/J.SEMNUCLMED.2011.02.005.
14. Z. Keidar, O. Israel, and Y. Krausz, "SPECT/CT in tumor imaging: Technical aspects and clinical applications," *Semin Nucl Med*, vol. 33, no. 3, pp. 205–218, Jul. 2003. https://doi.org/10.1053/SNUC.2003.127310.
15. P. E. Kinahan, B. H. Hasegawa, and T. Beyer, "X-ray-based attenuation correction for positron emission tomography/computed tomography scanners," *Semin Nucl Med*, vol. 33, no. 3, pp. 166–179, Jul. 2003. https://doi.org/10.1053/SNUC.2003.127307.
16. R. Minamimoto *et al.*, "Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI," *Mol Imaging Biol*, vol. 18, no. 5, pp. 776–781, Oct. 2016. https://doi.org/10.1007/s11307-016-0939-8.

17. V. Balaji, T. A. Song, M. Malekzadeh, P. Heidari, and J. Dutta, "Artificial Intelligence for PET and SPECT Image Enhancement," *Journal of Nuclear Medicine*, vol. 65, no. 1, Jan. 2024. https://doi.org/10.2967/jnumed.122.265000.
18. E. Prieto *et al.*, "Brain PET imaging optimization with time of flight and point spread function modelling," *Physica Medica*, vol. 31, no. 8, pp. 948–955, Dec. 2015. https://doi.org/10.1016/J.EJMP.2015.07.001.
19. G. Krokos, J. MacKewn, J. Dunn, and P. Marsden, "A review of PET attenuation correction methods for PET-MR," Dec. 01, 2023, *Springer Science and Business Media Deutschland GmbH*. https://doi.org/10.1186/s40658-023-00569-0.
20. A. P. King, C. Tsoumpas, C. Buerger, V. Schulz, P. Marsden, and T. Schaeffter, *Real-Time Respiratory Motion Correction for Simultaneous PET-MR Using an MR-Derived Motion Model*.
21. U. Javed, M. M. Riaz, A. Ghafoor, S. S. Ali, and T. A. Cheema, "MRI and PET image fusion using fuzzy logic and image local features," *The Scientific World Journal*, vol. 2014, 2014. https://doi.org/10.1155/2014/708075.
22. H. Arabi, A. AkhavanAllaf, A. Sanaat, I. Shiri, and H. Zaidi, "The promise of artificial intelligence and deep learning in PET and SPECT imaging," *Physica Medica*, vol. 83, pp. 122–137, Mar. 2021. https://doi.org/10.1016/J.EJMP.2021.03.008.
23. Y. Bouchareb *et al.*, "Technological Advances in SPECT and SPECT/CT Imaging," Jul. 01, 2024, *Multidisciplinary Digital Publishing Institute (MDPI)*. https://doi.org/10.3390/diagnostics14131431.
24. A. D. Shanbhag *et al.*, "Deep Learning-Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT," *J Nucl Med*, vol. 64, no. 3, pp. 472–478, Mar. 2023. https://doi.org/10.2967/jnumed.122.264429.
25. N. Aloysius and M. Geetha, "A review on deep convolutional neural networks," in *Proceedings of the 2017 IEEE International Conference on Communication and Signal Processing, ICCSP 2017*, Institute of Electrical and Electronics Engineers Inc., Jul. 2017, pp. 588–592. https://doi.org/10.1109/ICCSP.2017.8286426.
26. K. Lakhdari and N. Saeed, "A new vision of a simple 1D Convolutional Neural Networks (1D-CNN) with Leaky-ReLU function for ECG abnormalities classification," *Intell Based Med*, vol. 6, p. 100080, Jan. 2022. https://doi.org/10.1016/J.IBMED.2022.100080.
27. M. Kuchana, A. Srivastava, R. Das, J. Mathew, A. Mishra, and K. Khatter, "AI aiding in diagnosing, tracking recovery of COVID-19 using deep learning on Chest CT scans," *Multimed Tools Appl*, vol. 80, no. 6, pp. 9161–9175, Mar. 2021. https://doi.org/10.1007/s11042-020-10010-8.
28. R. Saravanan and Pothula Sujatha, *Proceeding of the 2018 International Conference on Intelligent Computing and Control Systems (ICICCS) : June 14-15, 2018*, ICICCS 2018., vol. 18. Puducherry: [IEEE], 2018.
29. H. U. Dike, Y. Zhou, K. K. Deveerasetty, and Q. Wu, "Unsupervised Learning Based On Artificial Neural Network: A Review," in *2018 IEEE International Conference on Cyborg and Bionic Systems, CBS 2018*, Institute of Electrical and Electronics Engineers Inc., Jul. 2018, pp. 322–327. https://doi.org/10.1109/CBS.2018.8612259.
30. H. Ali, F. Mohsen, and Z. Shah, "Improving diagnosis and prognosis of lung cancer using vision transformers: a scoping review," *BMC Med Imaging*, vol. 23, no. 1, Dec. 2023. https://doi.org/10.1186/s12880-023-01098-z.
31. P. B. Johnson, L. A. Young, N. Lamichhane, V. Patel, F. M. Chinea, and F. Yang, "Quantitative imaging: Correlating image features with the segmentation accuracy of PET based tumor contours in the lung," *Radiotherapy and Oncology*, vol. 123, no. 2, pp. 257–262, May 2017. https://doi.org/10.1016/J.RADONC.2017.03.008.
32. M. S. Sadaghiani, S. P. Rowe, and S. Sheikhbahaei, "Applications of artificial intelligence in oncologic 18F-FDG PET/CT imaging: a systematic review," *Ann Transl Med*, vol. 9, no. 9, pp. 823–823, May 2021. https://doi.org/10.21037/atm-20-6162.
33. J. A. Scott, S. McDermott, A. Kilcoyne, Y. Wang, E. F. Halpern, and J. B. Ackman, "Comparison of 18F-FDG avidity at PET of benign and malignant pure ground-glass opacities: a paradox? Part II: artificial neural network integration of the PET/CT characteristics of ground-glass opacities to predict their likelihood of malignancy," *Clin Radiol*, vol. 74, no. 9, pp. 692–696, Sep. 2019. https://doi.org/10.1016/J.CRAD.2019.04.024.

34. S. Wu *et al.*, "Development and Validation of an MRI-Based Radiomics Signature for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer," *EBioMedicine*, vol. 34, pp. 76–84, Aug. 2018. https://doi.org/10.1016/j.ebiom.2018.07.029.
35. Z. Guo, N. Guo, K. Gong, S. Zhong, and Q. Li, "Gross tumor volume segmentation for head and neck cancer radiotherapy using deep dense multi-modality network," *Phys Med Biol*, vol. 64, no. 20, Oct. 2019. https://doi.org/10.1088/1361-6560/ab440d.
36. X. Dong *et al.*, "Deep learning-based attenuation correction in the absence of structural information for whole-body positron emission tomography imaging," *Phys Med Biol*, vol. 65, no. 5, 2020. https://doi.org/10.1088/1361-6560/ab652c.
37. S. Ellmann *et al.*, "Prediction of early metastatic disease in experimental breast cancer bone metastasis by combining PET/CT and MRI parameters to a Model-Averaged Neural Network," *Bone*, vol. 120, pp. 254–261, Mar. 2019. https://doi.org/10.1016/J.BONE.2018.11.008.
38. M. R. King, "The Future of AI in Medicine: A Perspective from a Chatbot," Feb. 01, 2023, *Springer*. https://doi.org/10.1007/s10439-022-03121-w.